Patents Assigned to AROG PHARMACEUTICALS, INC.
  • Crenolanib for treating FLT3 mutated proliferative disorders
    Patent number: 9393240
    Abstract: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: July 19, 2016
    Assignee: AROG PHARMACEUTICALS, INC.
    Inventor: Vinay K. Jain
  • Crenolanib for treating FLT3 mutated proliferative disorders
    Patent number: 9101624
    Abstract: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: August 11, 2015
    Assignee: AROG PHARMACEUTICALS, INC.
    Inventor: Vinay K. Jain